亿帆医药（002019）8月8日主力资金净流出5717.18万元

Core Insights - Yifan Pharmaceutical (002019) reported a closing price of 14.69 yuan as of August 8, 2025, reflecting a decline of 1.67% [1] - The company experienced a net outflow of main funds amounting to 57.17 million yuan, which accounted for 19.13% of the total transaction amount [1] - The latest quarterly report indicated total revenue of 1.327 billion yuan, a year-on-year growth of 0.05%, and a net profit attributable to shareholders of 153 million yuan, up 4.83% year-on-year [1] Financial Performance - The company's total revenue for Q1 2025 was 1.327 billion yuan, with a slight increase of 0.05% compared to the previous year [1] - Net profit attributable to shareholders reached 153 million yuan, representing a year-on-year increase of 4.83% [1] - The company's non-recurring net profit was 95.37 million yuan, showing a decrease of 13.55% year-on-year [1] - Key financial ratios include a current ratio of 1.370, a quick ratio of 0.984, and a debt-to-asset ratio of 31.36% [1] Company Overview - Yifan Pharmaceutical Co., Ltd. was established in 2000 and is located in Hangzhou, primarily engaged in research and experimental development [1] - The company has a registered capital of 12.1639 billion yuan, which is also its paid-in capital [1] - The legal representative of the company is Cheng Xianfeng [1] Investment and Intellectual Property - Yifan Pharmaceutical has made investments in 18 external companies and participated in 5 bidding projects [2] - The company holds 23 trademark registrations and 11 patents, along with 12 administrative licenses [2]